Long-Term Management of Alcoholic Liver Disease

Clinics in Liver Disease

Volumn 20, Issue 3, 2016, Pages 551-562

  Allampati, Sanath ^a   Mullen, Kevin D ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Abstinence; Alcoholic liver disease; Hepatocellular carcinoma; Recidivism; Varices

Indexed keywords

ALCOHOL; COLCHICINE; PROPYLTHIOURACIL; S ADENOSYLMETHIONINE; SILYMARIN; DRUGS USED IN THE TREATMENT OF ADDICTION;

ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOLISM; CAUSE OF DEATH; DIAGNOSTIC IMAGING; DISABILITY; DISEASE COURSE; EARLY DIAGNOSIS; ENDOSCOPY; ESOPHAGUS VARICES BLEEDING; FOLLOW UP; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MORBIDITY; MORTALITY; NUTRITION; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RECIDIVISM; REVIEW; UNITED STATES; ALGORITHM; BIOPSY; CARCINOMA, HEPATOCELLULAR; DRINKING BEHAVIOR; ESOPHAGEAL AND GASTRIC VARICES; LIVER; LIVER CIRRHOSIS, ALCOHOLIC; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; PATHOLOGY; PRIMARY HEALTH CARE; RISK FACTOR;

ALCOHOL ABSTINENCE; ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOLISM; ALGORITHMS; BIOPSY; CARCINOMA, HEPATOCELLULAR; ESOPHAGEAL AND GASTRIC VARICES; HUMANS; LIVER; LIVER CIRRHOSIS, ALCOHOLIC; LIVER DISEASES, ALCOHOLIC; LIVER NEOPLASMS; PRIMARY HEALTH CARE; RISK FACTORS;

EID: 84962425239     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2016.02.011     Document Type: Review

References (44)

1. 1 O'Shea, R.S., Dasarathy, S., McCullough, A.J. Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 51 (2010), 307–328.
2. 2 Kitchens, J.M., Does this patient have an alcohol problem?. JAMA 272:22 (1994), 1782–1787.
3. 3 World Health Organization, Evidence-based strategies and interventions to reduce alcohol-related harm. Global assessment of public-health problems caused by harmful use of alcohol; 60th World Health Assembly - A60/14 Add1. 2007, World Health Organization, Geneva (Switzerland).
4. 4 U.S. Preventive Services Task Force, Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement. Ann Intern Med 140:7 (2004), 554–556.
5. 5 Girela, E., Villanueva, E., Hernandez-Cueto, C., et al. Comparison of the CAGE questionnaire versus some biochemical markers in the diagnosis of alcoholism. Alcohol Alcohol 29:3 (1994), 337–343.
6. 6 Aalto, M., Seppä, K., Use of laboratory markers and the audit questionnaire by primary care physicians to detect alcohol abuse by patients. Alcohol Alcohol 40:6 (2005), 520–523.
7. 7 Skinner, H.A., Sheu, W.J., Reliability of alcohol use indices. The lifetime drinking history and the MAST. J Stud Alcohol 43:11 (1982), 1157–1170.
8. 8 Kenna, G.A., McGeary, J.E., Swift, R.M., Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1. Am J Health Syst Pharm 61 (2004), 2272–2279.
9. 9 Garbutt, J.C., Kranzler, H.R., O'Malley, S.S., et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293 (2005), 1617–1625.
10. 10 Rösner, S., Hackl-Herrwerth, A., Leucht, S., et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev(9), 2010 CD004332.
11. 11 Leone, M.A., Vigna-Taglianti, F., Avanzi, G., et al. Gammahydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev(2), 2010 CD006266.
12. 12 Crabb, D.W., Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med 48 (1999), 184–188.
13. 13 Leevy, C.M., Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine (Baltimore) 41 (1962), 249–276.
14. 14 Jaurigue, M.M., Cappell, M.S., Therapy for alcoholic liver disease. World J Gastroenterol 20:9 (2014), 2143–2158.
15. 15 Uchida, T., Kao, H., Quispe-Sjogren, M., et al. Alcoholic foamy degeneration–a pattern of acute alcoholic injury of the liver. Gastroenterology 84:4 (1983), 683–692.
16. 16 Bird, G.L., Investigation of alcoholic liver disease. Baillieres Clin Gastroenterol 7 (1993), 663–682.
17. 17 Mathurin, P., Poynard, T., Ramond, M.J., et al. Interet de la biopsie hepatique pour la selection des sujets suspects d'hepatitealcoolique aigue. [Abstract] Gastroenterol Clin Biol, 16, 1992, A231.
18. 18 Bruha, R., Dvorak, K., Petrtyl, J., Alcoholic liver disease. World J Hepatol 4:3 (2012), 81–90.
19. 19 Mendenhall, C.L., Anderson, S., Weesner, R.E., et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 76 (1984), 211–222.
20. 20 Mezey, E., Interaction between alcohol and nutrition in the pathogenesis of alcoholic liver disease. Semin Liver Dis 11 (1991), 340–348.
21. 21 Zenith, L., Meena, N., Ramadi, A., et al. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. Clin Gastroenterol Hepatol 12:11 (2014), 1920–1926.e2.
22. 22 de Franchis, R., Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 33 (2000), 846–852.
23. 23 de Franchis, R., Evolving Consensus in Portal Hypertension report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 43 (2005), 167–176.
24. 24 Wiest, R., Groszmann, R.J., Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 19 (2000), 411–426.
25. 25 Sikuler, E., Kravetz, D., Groszmann, R.J., Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 248:6 Pt 1 (1985), G618–G625.
26. 26 Pagliaro, L., D'Amico, G., Pasta, L., et al. Portal hypertension in cirrhosis: natural history. Bosch, J., Groszmann, R.J., (eds.) Portal hypertension. Pathophysiology and treatment, 1994, Blackwell Scientific, Oxford (United Kingdom), 72–92.
27. 27 Merli, M., Nicolini, G., Angeloni, S., et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 38 (2003), 266–272.
28. 28 Groszmann, R.J., Garcia-Tsao, G., Bosch, J., et al., Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353 (2005), 2254–2261.
29. 29 Casado, M., Bosch, J., Garcia-Pagan, J.C., et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 114 (1998), 1296–1303.
30. 30 Grace, N.D., Groszmann, R.J., Garcia-Tsao, G., et al. Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology 28 (1998), 868–880.
31. 31 D'Amico, G., Garcia-Tsao, G., Cales, P., et al. Diagnosis of portal hypertension: how and when. de Franchis, R., (eds.) Portal Hypertension III. Proceedings of the Third Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies, 2001, Blackwell Science, Oxford (United Kingdom), 36–64.
32. 32 The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices, Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 319 (1988), 983–989.
33. 33 D'Amico, G., de Franchis, R., Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 38 (2003), 599–612.
34. 34 Sarin, S.K., Lahoti, D., Saxena, S.P., et al. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 16 (1992), 1343–1349.
35. 35 Kim, T., Shijo, H., Kokawa, H., et al. Risk factors for hemorrhage from gastric fundal varices. Hepatology 25 (1997), 307–312.
36. 36 Thompson Coon, J., Rogers, G., Hewson, P., et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 11:34 (2007), 1–206.
37. 37 Kanwal, F., Kramer, J., Asch, S.M., et al. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol 8:8 (2010), 709–717.
38. 38 Bruix, J., Sherman, M., American Association for the Study of Liver Diseases, Management of hepatocellular carcinoma: an update. Hepatology 53 (2010), 1020–1022.
39. 39 El-Serag, H.B., Mason, A.C., Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:10 (1999), 745–750.
40. 40 Deuffic, S., Poynard, T., Buffat, L., et al. Trends in primary liver cancer. Lancet 351:9097 (1998), 214–215.
41. 41 Allen, N.E., Beral, V., Casabonne, D., et al. Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst, 101(5), 2009, 296.
42. 42 Zhang, S.M., Lee, I.M., Manson, J.E., et al. Alcohol consumption and breast cancer risk in the Women's Health Study. Am J Epidemiol, 165(6), 2007, 667.
43. 43 Chen, W.Y., Rosner, B., Hankinson, S.E., et al. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA, 306(17), 2011, 1884.
44. 44 Schutze, M., Boeing, H., Pischon, T., et al. Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ, 342, 2011, 1584.